Suppr超能文献

[吉西他滨与培美曲塞:新的联合应用及耐药机制]

[Gemcitabine and pemetrexed: novel associations and mechanisms of resistance].

作者信息

Sablin Marie-Paule, Le Tourneau Christophe, El Maalouf Ghassan, Raymond Eric, Faivre Sandrine

机构信息

Service inter-hospitalier de cancérologie Bichat-Beaujon, 100 boulevard du Général Leclerc, 92118 Clichy.

出版信息

Bull Cancer. 2007;94 Spec No Actualites:S149-54.

Abstract

Gemcitabine and pemetrexed are two novel antimetabolites with broad spectrum of antitumor activity and a safe toxicity profile. In addition, recent advances in cellular and molecular biology led to a better understanding of their mechanisms of action and resistance. Based on these latter advantages, several studies have been conducted using pemetrexed or gemcitabine either alone or with novel targeted therapies. Taken together, these recent data should result in a better and more specific use of these two very promising drugs.

摘要

吉西他滨和培美曲塞是两种新型抗代谢药物,具有广泛的抗肿瘤活性且毒性特征安全。此外,细胞生物学和分子生物学的最新进展使人们对它们的作用机制和耐药性有了更好的理解。基于这些优势,已经开展了多项单独使用培美曲塞或吉西他滨,或与新型靶向治疗联合使用的研究。综上所述,这些最新数据应能使这两种非常有前景的药物得到更好、更具针对性的应用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验